Biopharmaceutical company Octapharma USA, is currently accepting applications for its research grants program. The deadline for grant submissions is Wednesday, March 31, 2010.

 

The Octapharma 25th Anniversary Grants Program supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. The grants, which are available to U.S.-based researchers, are administered by Octapharma USA.

  

Octapharma AG, which manufactures plasma products, launched the grants program last year in celebration of the company's 25th anniversary. Applications, which are only accepted online at www.octapharmagrants.com, will be evaluated by the Octapharma Grants Committee in April. Recipients will be announced shortly afterward.

 

“The grants program has been very well received and we expect to be announcing our first recipient shortly,” said Octapharma USA President Flemming Nielsen.” The U.S. market is very important to Octapharma and the grants program is just one way that we demonstrate our commitment. Our vision of providing patients with the safest, highest quality products available is stronger than ever.”

 

Source: PR Newswire, February 4, 2010